Management of Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia.
Gang WangChang-Su HanChia-Yih LiuSandra ChanTadafumi KatoWilson TanLili ZhangYu FengChee H NgPublished in: Neuropsychiatric disease and treatment (2020)
Taking into account the survey results, the expert panel made general recommendations on the management of TRD. TRD partial-responders to antidepressants should be considered for augmentation with second-generation antipsychotics. For non-responders, switching to another class of antidepressants ought to be considered. TRD patients achieving remission with acute treatment should consider continuing their antidepressants for at least another 6 months to prevent relapse. ECT is a treatment consideration for patients with severe depression or persistent symptoms despite multiple adequate trials of antidepressants. Physicians should also consider the response, tolerability and adherence to the current and previous antidepressants, the severity of symptoms, comorbidities, concomitant medications, preferences, and cost when choosing a TRD treatment approach for each individual patient.